| This is a paid advertisement. Full disclosures and risk factors are provided at the bottom of this email. |
In November 2026, the patent on Bristol-Myers Squibb's blood thinner Eliquis expires.
And just like that, nearly $14.3 billion a year in revenue will go up in smoke, as generics step in and gobble up 80% to 90% of the market.
Worse yet — at least for Big Pharma — the patent on Merck's blockbuster cancer drug, Keytruda, expires in December 2028. The result: $32.6 billion a year in revenue will nearly disappear.
Then there's Johnson & Johnson's cancer drug, Darzalex. Its patent expires in May 2029, taking nearly $17.8 billion of annual revenue with it.
That's just three examples of a devastating $300 billion "patent cliff" facing big pharmaceutical companies over the next few years as patent after patent expires.
A cliff that will leave them with gaping revenue holes they need to fill quickly.
And it seems almost certain that they'll move to replace some of that disappearing revenue by acquiring smaller companies with promising new drugs.
With that in mind, I've got my eye on an up and coming biotech that could be exactly what they're looking for.
It's a NASDAQ company that's developing breakthrough drugs for mental health issues.
And clinical trials show that its new drugs — based on patented novel compounds — work better than anything Big Pharma has ever come up with.
When you consider that 300 million people around the world suffer from depression and anxiety, it's clear there's a ready market for these breakthroughs.
All this could be enough to make the company a potentially enticing takeover target for a multi-billion pharmaceutical company looking to replace some of the revenue lost to those expiring patents.
And that could be good news for the company and investors who own its undervalued shares.
Before I go on, allow me to introduce myself. My name is Jon Najarian. I'm a former NFL football player who traded in his cleats more than four decades ago to launch what has turned out to be a more successful career in the financial markets.
With my brother Pete, I run the Rebel Investors Club, which provides potentially high-profit investment advice to Main Street investors.
And our analysis shows that this NASDAQ company could be our next big winner — whether a big pharmaceutical makes a play for the company or not.
But if does happen, we could see the company's shares take off, as happened when…
- Pfizer bought cancer-drug maker Seagen and shareholders walked away with a 30%–40% premium over its price when the acquisition was announced…
- Bristol-Myers Squibb acquired MyoKardia, which saw its stock soar 2,150% higher over its IPO price from five years earlier…
- Jazz Pharmaceuticals bought GW Pharmaceuticals, the culmination of a nice run that saw GW's stock soar 2,371% over eight years.
Now, don't get me wrong. Neither my brother nor I ever would ever recommend investing in a company based solely on its acquisition potential.
While it's always a possibility, it's never something to count on. Instead we recommend you look at it as potential icing on the cake.
In any case, with this biotech, we see all the makings of a company that could be going places and potentially handing early investors nice returns.
And getting in now, while the company is still in its early stages, could bring you some rich rewards — even if the company is never acquired.
You can get the full story in an exclusive Research Report we recently completed. It's called Big Pharma Failure Creates Massive Investment Opportunity, and it reveals seven reasons why this unique company could be a big winner for your portfolio.
To get your free, no-obligation copy of this $99.95-value Report, click here, and you can download it immediately.
We're encouraging our Rebel Investors Club members to consider jumping on this opportunity with this company now… and it's an opportunity you'd be well served to consider too.
Click here to claim your free Research Report today.
Sincerely,
Jon and Pete Najarian, Editors
Rebel Investors Club |
IMPORTANT NOTICE AND DISCLAIMER: All investments are subject to risk, which must be considered on an individual basis before making any investment decision. This paid advertisement includes a stock profile of Helus Pharma (NASDAQ: HELP). Rebel Investors Club is an investment newsletter being advertised herein. This paid advertisement is intended solely for information and educational purposes and is not to be construed under any circumstances as an offer to sell or a solicitation of an offer to purchase any securities. In an effort to enhance public awareness, Helus Pharma (NASDAQ: HELP) provided advertising agencies with a total budget of approximately $2,914,712 and is the sole source of funds to cover the costs associated with creating, printing and distribution of this advertisement. From that total budget, Moneta Advisory Partners, an affiliate of Rebel Investors Club was paid $500,000 as a research fee and for the production and placement of additional advertising media for this campaign. The advertising agencies will retain any excess sums after all expenses are paid. Rebel Investors Club may receive subscription revenue in the future from new subscribers as a result of this advertisement for its newsletter. While this advertisement is being disseminated and for a period of not less than 90 days thereafter, Rebel Investors Club , the advertising agencies, and their respective officers, principals, or affiliates will not sell securities of Helus Pharma (NASDAQ: HELP). If successful, this advertisement will increase investor and market awareness of Helus Pharma (NASDAQ: HELP) and its securities, which may result in an increased number of shareholders owning and trading the securities, increased trading volume, and possibly an increase in share price, which may be temporary. This advertisement, the advertising agencies and Rebel Investors Club do not purport to provide a complete analysis of Helus Pharma (NASDAQ: HELP) or its financial position. They are not, and do not purport to be, broker-dealers or registered investment advisors. This advertisement is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a registered broker-dealer or registered investment advisor or, at a minimum, doing your own research if you do not utilize an investment professional to make decisions on what securities to buy and sell, and only after reviewing the financial statements and other pertinent publicly-available information about Helus Pharma (NASDAQ: HELP). Further, readers are specifically urged to read and carefully consider the Risk Factors identified and discussed in Helus Pharma (NASDAQ: HELP) SEC filings. Investing in microcap securities such as Helus Pharma (NASDAQ: HELP) is speculative and carries a high degree of risk. Past performance does not guarantee future results. This advertisement is based exclusively on information generally available to the public and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the advertising agencies and Rebel Investors Club cannot guarantee the accuracy or completeness of the information and are not responsible for any errors or omissions. This advertisement contains forward-looking statements, including statements regarding expected continual growth of Helus Pharma (NASDAQ: HELP) and/or its industry. The advertising agencies and Rebel Investors Club note that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect Helus Pharma (NASDAQ: HELP) actual results of operations. Factors that could cause actual results to vary include the size and growth of the market for Helus Pharma (NASDAQ: HELP) products and/or services, the company's ability to fund its capital requirements in the near term and long term, federal and state regulatory issues, pricing pressures, etc. Rebel Investors Club is the publisher's trademark. All trademarks used in this advertisement other than Rebel Investors Club are the property of their respective trademark holders and no endorsement by such owners of the contents of this advertisement is made or implied. The advertising agencies and Rebel Investors Club are not affiliated, connected, or associated with, and are not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made to any rights in any third-party trademarks. |
DISCLOSURES - THIS IS A PAID ADVERTISEMENT. This is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote public and private companies. By reading this email, our website / media webpage you agree to the terms of our disclosure, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor's, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage. In connection with this advertising e-mail campaign, The Darwin Agency, Inc, DBA Darwin Investor Network, and its owners, managers, employees, and assigns Creative Direct Marketing Group has been paid by the profiled company or a third party to disseminate this communication. In this case, the Company has been paid by CEA Industries Inc., $7,500USD. This compensation is a major conflict with our ability to be unbiased. NOT AN INVESTMENT ADVISER. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment. RISK OF INVESTING. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our featured profiles on the highlighted companies. Gains mentioned in our website / media webpage(s) may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. The past performance of any trading system or methodology is not necessarily indicative of future results. All trades, patterns, charts, systems, etc., discussed in this message and the product materials are for illustrative purposes only and not to be construed as specific advisory recommendations. All ideas and material presented are entirely those of the author and do not necessarily reflect those of the publisher.
For official filings and investor disclosures, visit:
Helus Pharma SEDAR+ Filings
Helus Pharma Investor Relations Page
By reading this communication, you agree to the terms of this disclaimer, including releasing the Company, its affiliates, owners, and assigns from any and all liability, damages, or injury resulting from the information contained herein. You acknowledge that you are solely responsible for any financial or investment decisions based on this communication. |
|
 |
|
| | Advertising Disclosure: This email may contain paid advertisements. Summa Money publishes 4 newsletters with various areas of focus. The Ivy is delivered 3x per week with a focus on investments that could generate passive income. The Burst is delivered 2x per week with a focus on growth stocks. The Spotlight is delivered 1x per week with a focus on high potential stocks and economic insights. The Daily is an occasional newsletter with a focus on the best investing stories and news from around the world. We hope you enjoy them all, but feel free to unsubscribe from the content you do not want to receive. If you do not wish to receive this email, then we apologize for the inconvenience. You can immediately discontinue receiving this email by clicking the unsubscribe link at the bottom of this email. If you have any questions, please send an email with your questions to support@summamoney.com. Nothing in this email should be considered personalized financial advice. We strongly urge you to read our full disclaimer here. If you can't see this message, view it in your browser. You are receiving this e-mail at indra21poetra@gmail.com as a part of your free subscription to the Ivy Newsletter. To read our privacy policy follow this link. or To unsubscribe by mail, write us at: Summa Money | 2319 N Andrews Ave. Fort Lauderdale, FL 33311 Website: Summa Money Nothing in this email should be considered personalized financial advice. Staff members at Summa Money are not qualified to answer your investing-related questions as they are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Copyright 2024 Summa Money. All rights reserved. Advertise With Us |
|
|
Tidak ada komentar:
Posting Komentar